CytomX Therapeutics shares yo-yoed this past week, surging on positive early clinical data for its colorectal cancer candidate, then retreating on investor questions about the data. Also, Eli Lilly ...

Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor ...

The life science industry employs 18,000 people in central Ohio and 64,000 across the state, according to the Ohio Life Sciences Association.

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Findings from preclinical studies could point to therapeutic strategies for Huntington’s disease, as well as other neurodegenerative disorders and potentially cancer.

A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.

To test whether AT2‑derived lipids are required for metastasis, the researchers selectively deleted Fasn in AT2 cells.

The model has the potential to transform the ability to study telomere biology, learn more about human aging, and ultimately help people preserve better health as they age.

Nautilus debuted its platform at the US HUPO meeting last month and is seeking additional participants for its ongoing early access program.

Researchers say discovery could establish the basis for a novel, tandem biomarker-peptide therapeutic approach to schizophrenia.

Roche’s AI factories, protein design reasoning model, and healthcare robotics are among GTC announcements for biology.

Cayman advanced the protocol from a 1-L setup to a 100-L pilot run, operating the reaction and analysis independently.